NO20090029L - Pyrrolopyrimidiner for farmasoytiske formuleringer - Google Patents

Pyrrolopyrimidiner for farmasoytiske formuleringer

Info

Publication number: NO20090029L
Authority: NO; Norway
Prior art keywords: pyrrolopyrimidines; pharmaceutical formulations; pyrrolopyrimidine compounds; pharmaceutical compositions; relates
Prior art date: 2006-07-10

Application number

NO20090029A

Other languages

English (en)

Norwegian (no)

Inventor

Thomas Stephen Coulter

Stephen Murfin

Tanja Reuter

Steven Taylor

Stefan Jakel

Original Assignee

Develogen Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-07-10

Filing date

2009-01-05

Publication date

2009-01-28

2009-01-05 Application filed by Develogen Ag filed Critical Develogen Ag

2009-01-28 Publication of NO20090029L publication Critical patent/NO20090029L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Neurology (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Ophthalmology & Optometry (AREA)
Biomedical Technology (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)

NO20090029A 2006-07-10 2009-01-05 Pyrrolopyrimidiner for farmasoytiske formuleringer NO20090029L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP06014297A EP1889847A1 (fr)	2006-07-10	2006-07-10	Dérivés de pyrrolopyrimidine pour applications pharmaceutiques
PCT/EP2007/006109 WO2008006547A2 (fr)	2006-07-10	2007-07-10	Pyrrolopyrimidines pour compositions pharmaceutiques

Publications (1)

Publication Number	Publication Date
NO20090029L true NO20090029L (no)	2009-01-28

Family

ID=37496429

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20090029A NO20090029L (no)	2006-07-10	2009-01-05	Pyrrolopyrimidiner for farmasoytiske formuleringer

Country Status (16)

Country	Link
US (1)	US8697713B2 (fr)
EP (2)	EP1889847A1 (fr)
JP (1)	JP5331951B2 (fr)
KR (1)	KR20090039757A (fr)
CN (1)	CN101511837A (fr)
AT (1)	ATE526331T1 (fr)
AU (1)	AU2007271928A1 (fr)
BR (1)	BRPI0712882A2 (fr)
CA (1)	CA2690277A1 (fr)
CO (1)	CO6150162A2 (fr)
EA (1)	EA200900136A1 (fr)
IL (1)	IL196391A0 (fr)
MX (1)	MX2009000333A (fr)
NO (1)	NO20090029L (fr)
WO (1)	WO2008006547A2 (fr)
ZA (1)	ZA200810785B (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8633201B2 (en)	2006-04-07	2014-01-21	Boehringer Ingelheim International Gmbh	Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions
EP1889847A1 (fr)	2006-07-10	2008-02-20	DeveloGen Aktiengesellschaft	Dérivés de pyrrolopyrimidine pour applications pharmaceutiques
US8946239B2 (en)	2008-07-10	2015-02-03	Duquesne University Of The Holy Spirit	Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
EP2331551B1 (fr)	2008-08-26	2016-06-29	Evotec International GmbH	Thiénopyrimidines pour compositions pharmaceutiques
UY33241A (es)	2010-02-26	2011-09-30	Boehringer Ingelheim Int	?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
JP5575274B2 (ja)	2010-02-26	2014-08-20	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	医薬組成物のためのｍｎｋｌ／ｍｎｋ２阻害活性を有する４−［シクロアルキルオキシ（ヘテロ）アリールアミノ］チエノ「２，３−ｄ］ピリミジン
EP2539343B1 (fr) *	2010-02-26	2015-12-30	Evotec International GmbH	Thiénopyrimidines contenant un groupe alkyle substitué pour des compositions pharmaceutiques
JP2013520473A (ja) *	2010-02-26	2013-06-06	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	医薬組成物用のＭｎｋ１／Ｍｎｋ２阻害活性を有するハロゲン又はシアノ置換されたチエノ［２，３−ｄ］ピリミジン
JP5907986B2 (ja)	2010-11-29	2016-04-26	ガリオンファーマシューティカルズインコーポレイテッド	呼吸制御障害または呼吸制御疾患の処置用の呼吸刺激薬としての化合物
US20120295911A1 (en)	2010-11-29	2012-11-22	Galleon Pharmaceuticals, Inc.	Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
KR101286743B1 (ko) *	2011-02-18	2013-07-15	충남대학교산학협력단	페노피브레이트를 함유하는 패혈증 예방용 약학 조성물
ES2650915T3 (es) *	2011-12-12	2018-01-23	Bayer Intellectual Property Gmbh	Imidazopiridazinas amino-sustituidas
CA2873971A1 (fr) *	2012-05-21	2013-11-28	Bayer Pharma Aktiengesellschaft	Pyrrolopyrimidines substituees
US11186575B2 (en)	2012-08-07	2021-11-30	Alber Einslein College of Medicine	Treatment of helicobacter pylori infections
EP2900671A1 (fr) *	2012-09-26	2015-08-05	Bayer Pharma Aktiengesellschaft	Indazol-pyrrolopyrimidines substituées utiles dans le traitement de maladies hyperprolifératives
CN104781260A (zh) *	2012-09-26	2015-07-15	拜耳制药股份公司	用于治疗过度增殖性障碍的取代的吲唑-吡咯并嘧啶
WO2014072244A1 (fr) *	2012-11-09	2014-05-15	Boehringer Ingelheim International Gmbh	Quinazolines substituées par sulfoximine pour compositions pharmaceutiques
ES2653419T3 (es) *	2013-02-01	2018-02-07	Bayer Pharma Aktiengesellschaft	Pirazolopirimidinilamino-indazoles sustituidos
WO2014145576A2 (fr)	2013-03-15	2014-09-18	Northwestern University	Pyrrolo(2,3-d)pyrimidines substituées pour le traitement du cancer
AU2014301295C1 (en) *	2013-06-28	2018-03-15	Evotec International Gmbh	Sulfoximine substituted quinazolines and their use as MNK1 and/or MNK2 kinase inhibitors
KR20160030239A (ko) *	2013-07-08	2016-03-16	바이엘 파마 악티엔게젤샤프트	치환된 피라졸로-피리딘아민
WO2015091156A1 (fr) *	2013-12-17	2015-06-25	Boehringer Ingelheim International Gmbh	Pyrrolotriazines à substitution sulfoximine pour compositions pharmaceutiques
EP3140300B1 (fr) *	2014-05-07	2019-08-14	Evotec International GmbH	Quinazolines substituées par une sulfoximine destinées à des compositions pharmaceutiques
TWI713455B (zh) *	2014-06-25	2020-12-21	美商伊凡克特治療公司	ＭｎＫ抑制劑及其相關方法
CN104225597A (zh) *	2014-09-29	2014-12-24	武汉大学	Mapk信号整合激酶1在治疗动脉粥样硬化中的功能和应用
ES2928714T3 (es)	2015-01-16	2022-11-22	Massachusetts Gen Hospital	Compuestos para mejorar el empalme del ARNm
DK3285809T3 (da)	2015-04-20	2019-11-18	Effector Therapeutics Inc	Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner.
US9708359B2 (en)	2015-08-06	2017-07-18	Chimerix, Inc.	Pyrrolopyrimidine nucleosides and analogs thereof
EA034440B1 (ru)	2015-10-29	2020-02-07	Эффектор Терапьютикс, Инк.	СОЕДИНЕНИЯ ПИРРОЛО-, ПИРАЗОЛО-, ИМИДАЗОПИРИМИДИНА И ПИРИДИНА, КОТОРЫЕ ИНГИБИРУЮТ Mnk1 И Mnk2
MX2018005204A (es)	2015-10-29	2018-08-01	Effector Therapeutics Inc	Inhibidores de isoindolina, azaisoindolina, dihidroindenona y dihidroazaindenona de cinasas 1 y 2 de interaccion con proteina cinasas activadas por mitogenos (mnk1 y mnk2).
GB201520499D0 (en) *	2015-11-20	2016-01-06	Medical Res Council Technology	Compounds
GB201520500D0 (en) *	2015-11-20	2016-01-06	Medical Res Council Technology	Compounds
US10000487B2 (en)	2015-11-20	2018-06-19	Effector Therapeutics, Inc.	Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers
US9630968B1 (en)	2015-12-23	2017-04-25	Arqule, Inc.	Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
US20170191136A1 (en)	2015-12-31	2017-07-06	Effector Therapeutics, Inc.	Mnk biomarkers and uses thereof
US20190117657A1 (en) *	2016-03-31	2019-04-25	South Australian Health And Medical Research Institute Limited	Method of inhibiting high fat diet-related conditions
GB2550977B (en)	2016-05-31	2020-07-22	Cirrus Logic Int Semiconductor Ltd	Monitoring of devices
BR112019003504A2 (pt)	2016-08-24	2019-05-21	Arqule, Inc.	compostos de amino-pirrolopirimidinona e métodos de uso dos mesmos
ES2969988T3 (es)	2017-02-14	2024-05-23	Effector Therapeutics Inc	Inhibidores de Mnk sustituidos con piperidina y métodos relacionados con los mismos
CN109020957B (zh) *	2017-06-12	2023-01-13	南京天印健华医药科技有限公司	作为mnk抑制剂的杂环化合物
ES3011607T3 (en)	2017-09-21	2025-04-07	Chimerix Inc	Morphic forms of 4-amino-7-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7h-pyrrolo(2,3-d)pyrimidine-5-carboxamide and uses thereof
ES3040411T3 (en)	2018-03-22	2025-10-30	Incarda Therapeutics Inc	A novel method to slow ventricular rate
WO2020086713A1 (fr)	2018-10-24	2020-04-30	Effector Therapeutics, Inc.	Formes cristallines d'inhibiteurs de mnk
CN110483527A (zh) *	2019-09-09	2019-11-22	陕西科技大学	一种4-氯吡咯[2,3-d]嘧啶取代化合物及其合成方法
US20220370463A1 (en) *	2019-09-19	2022-11-24	New York Society for the Relief of the Ruptured and Crippled, Maintaining the Hospital for Special S	Stabilized c-fms intracellular fragments (ficd) promote osteoclast differentiation and arthritic bone erosion
US11116737B1 (en)	2020-04-10	2021-09-14	University Of Georgia Research Foundation, Inc.	Methods of using probenecid for treatment of coronavirus infections

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH408945A (de)	1956-02-10	1966-03-15	Ciba Geigy	Verfahren zur Herstellung von heterocyclischen Verbindungen
DE3036390A1 (de)	1980-09-26	1982-05-13	Troponwerke GmbH & Co KG, 5000 Köln	Neue pyrrolo-pyrimidine, verfahren zu ihrer herstellung und ihre verwendung bei der herstellung von biologischen wirkstoffen
DD248593A1 (de)	1985-01-11	1987-08-12	Univ Halle Wittenberg	Verfahren zur herstellung von 4-basischsubstituierten thieno/2,3-d/pyrimidin-6-ylcarbonsaeureestern
DE4008726A1 (de)	1990-03-19	1991-09-26	Basf Ag	Thieno(2,3-d)pyrimidinderivate
AU651337B2 (en)	1990-03-30	1994-07-21	Dowelanco	Thienopyrimidine derivatives
TW370529B (en)	1992-12-17	1999-09-21	Pfizer	Pyrazolopyrimidines
IL112249A (en)	1994-01-25	2001-11-25	Warner Lambert Co	Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
ATE159257T1 (de)	1994-05-03	1997-11-15	Ciba Geigy Ag	Pyrrolopyrimidinderivate mit antiproliferativer wirkung
EP0729758A3 (fr)	1995-03-02	1997-10-29	Pfizer	Pyrazolopyrimidines et pyrrolopyrimidines pour traiter les troubles neuronaux et autres maladies
US6395733B1 (en)	1995-06-07	2002-05-28	Pfizer Inc	Heterocyclic ring-fused pyrimidine derivatives
SK72996A3 (en) *	1995-06-07	1997-04-09	Pfizer	Heterocyclic ring-fused pyrimidine derivatives and pharmaceutical compositions on their base
AR004010A1 (es)	1995-10-11	1998-09-30	Glaxo Group Ltd	Compuestos heterociclicos
WO1999024440A1 (fr)	1997-11-11	1999-05-20	Pfizer Products Inc.	Derives de thienopyrimidine et thienopyridine utiles comme agents anticancereux
US20030162795A1 (en)	1998-10-22	2003-08-28	Pfizer Inc.	Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
GB9906566D0 (en) *	1999-03-23	1999-05-19	Zeneca Ltd	Chemical compounds
US6643277B2 (en)	2000-06-29	2003-11-04	Harris Broadband Wireless Access, Inc.	Frequency re-use for point to multipoint applications
JP2005503345A (ja)	2001-04-30	2005-02-03	バイエル・コーポレーシヨン	新規な４−アミノ−５，６−置換チオフェノ［２，３−ｄ］ピリミジン
SE0102147D0 (sv)	2001-06-18	2001-06-18	Pharmacia Ab	New methods
DE60238929D1 (de)	2001-10-29	2011-02-24	Boehringer Ingelheim Int	Mnk-kinase-homologe proteine, die an der regulierung der energiehomöostase und dem organellen metabolismus beteiligt sind
WO2004037159A2 (fr)	2002-10-23	2004-05-06	Obetherapy Biotechnology	Composes, compositions et methodes permettant de moduler le metabolisme des graisses
US20050012622A1 (en)	2003-05-19	2005-01-20	Sutton William R.	Monitoring and control of sleep cycles
ES2304252T3 (es)	2003-05-28	2008-10-01	Universita Degli Studi Di Siena	Derivados sustituidos en posicion 4 de pirazolo(3,4-d)pirimidina y utilizaciones de los mismos.
MXPA05013227A (es)	2003-06-20	2006-03-09	Celltech R&D Ltd	Derivados de tienopiridona como inhibidores de cinasa.
EP1651652B1 (fr)	2003-07-24	2006-12-27	Bayer Pharmaceuticals Corporation	Composes tetrahydrobenzothienopyrimidinamine a substitution utiles pour le traitement de troubles hyper-proliferatifs
US7419978B2 (en)	2003-10-22	2008-09-02	Bristol-Myers Squibb Company	Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
CA2551689A1 (fr)	2004-01-05	2005-07-28	Merz Pharma Gmbh & Co. Kgaa	Memantine destinee au traitement de la maladie d'alzheimer legere et legere a moderee
US20050165029A1 (en) *	2004-01-13	2005-07-28	Ambit Biosciences Corporation	Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
EP1724268A4 (fr)	2004-02-20	2010-04-21	Kirin Pharma Kk	Compose ayant une activite d'inhibition du tgf-beta et composition pharmaceutique contenant celui-ci
GB0412467D0 (en)	2004-06-04	2004-07-07	Astrazeneca Ab	Chemical compounds
EP1773826A4 (fr)	2004-07-02	2009-06-03	Exelixis Inc	Modulateurs de c-met et leur methode d'utilisation
EP1746099A1 (fr) *	2004-12-23	2007-01-24	DeveloGen Aktiengesellschaft	Inhibiteurs de Mnk1 ou Mnk2
JP5328342B2 (ja)	2005-03-08	2013-10-30	ベーリンガーインゲルハイムインテルナツィオナールゲゼルシャフトミットベシュレンクテルハフツング	Ｍｎｋ−１タンパク質およびＭｎｋ−２タンパク質の結晶学的構造
WO2006124874A2 (fr)	2005-05-12	2006-11-23	Kalypsys, Inc.	Inhibiteurs de la b-raf kinase
BRPI0610322B8 (pt)	2005-05-20	2021-05-25	Methylgene Inc	inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica
EP1899353A1 (fr)	2005-06-22	2008-03-19	DeveloGen Aktiengesellschaft	Thienopyrimidines pour compositions pharmaceutiques
WO2007056214A2 (fr)	2005-11-02	2007-05-18	Cytovia, Inc	N-alkyl-n-aryl-thienopyrimidin-4-amines et analogues en tant qu'activateurs de caspases et inducteurs d'apoptose et utilisation associee
US20070099877A1 (en)	2005-11-02	2007-05-03	Cytovia, Inc.	N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2007059905A2 (fr)	2005-11-25	2007-05-31	Develogen Aktiengesellschaft	Nouvelle utilisation de thiénopyrimidines
EP1971611B1 (fr)	2005-12-21	2012-10-10	Abbott Laboratories	Composes anti-viraux
CN1990479A (zh)	2005-12-29	2007-07-04	中国科学院上海药物研究所	3－烷氧取代－2,5,7－三取代苯并吡喃－4－酮类化合物及其制备方法和包含该类化合物的药物组合物
US20080108611A1 (en)	2006-01-19	2008-05-08	Battista Kathleen A	Substituted thienopyrimidine kinase inhibitors
US8633201B2 (en)	2006-04-07	2014-01-21	Boehringer Ingelheim International Gmbh	Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions
ATE456565T1 (de)	2006-06-22	2010-02-15	Biovitrum Ab Publ	Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren
EP1889847A1 (fr)	2006-07-10	2008-02-20	DeveloGen Aktiengesellschaft	Dérivés de pyrrolopyrimidine pour applications pharmaceutiques
EP2219649A2 (fr)	2007-11-22	2010-08-25	Boehringer Ingelheim International Gmbh	Utilisation d'inhibiteurs de mnk pour le traitement de la maladie d'alzheimer
CN104135343B (zh)	2008-01-25	2018-02-06	华为技术有限公司	基站设备和方法
US20100015708A1 (en)	2008-06-18	2010-01-21	Mdrna, Inc.	Ribonucleic acids with non-standard bases and uses thereof
EP2331551B1 (fr)	2008-08-26	2016-06-29	Evotec International GmbH	Thiénopyrimidines pour compositions pharmaceutiques
EP2539343B1 (fr)	2010-02-26	2015-12-30	Evotec International GmbH	Thiénopyrimidines contenant un groupe alkyle substitué pour des compositions pharmaceutiques
JP2013520473A (ja)	2010-02-26	2013-06-06	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	医薬組成物用のＭｎｋ１／Ｍｎｋ２阻害活性を有するハロゲン又はシアノ置換されたチエノ［２，３−ｄ］ピリミジン
JP5575274B2 (ja)	2010-02-26	2014-08-20	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	医薬組成物のためのｍｎｋｌ／ｍｎｋ２阻害活性を有する４−［シクロアルキルオキシ（ヘテロ）アリールアミノ］チエノ「２，３−ｄ］ピリミジン
UY33241A (es)	2010-02-26	2011-09-30	Boehringer Ingelheim Int	?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
ES2583015T3 (es)	2011-09-07	2016-09-16	Nordex Energy Gmbh	Procedimiento para la fabricación de un componente de pala de rotor de instalación de energía eólica con un larguero principal prefabricado

2006
- 2006-07-10 EP EP06014297A patent/EP1889847A1/fr not_active Withdrawn
2007
- 2007-07-10 BR BRPI0712882-7A patent/BRPI0712882A2/pt not_active IP Right Cessation
- 2007-07-10 AU AU2007271928A patent/AU2007271928A1/en not_active Abandoned
- 2007-07-10 EA EA200900136A patent/EA200900136A1/ru unknown
- 2007-07-10 CN CNA2007800335380A patent/CN101511837A/zh active Pending
- 2007-07-10 WO PCT/EP2007/006109 patent/WO2008006547A2/fr not_active Ceased
- 2007-07-10 CA CA2690277A patent/CA2690277A1/fr not_active Abandoned
- 2007-07-10 KR KR1020097002707A patent/KR20090039757A/ko not_active Withdrawn
- 2007-07-10 MX MX2009000333A patent/MX2009000333A/es not_active Application Discontinuation
- 2007-07-10 AT AT07785972T patent/ATE526331T1/de not_active IP Right Cessation
- 2007-07-10 US US12/373,224 patent/US8697713B2/en active Active
- 2007-07-10 EP EP07785972A patent/EP2041137B1/fr not_active Not-in-force
- 2007-07-10 JP JP2009518781A patent/JP5331951B2/ja not_active Expired - Fee Related
2008
- 2008-12-22 ZA ZA200810785A patent/ZA200810785B/xx unknown
2009
- 2009-01-05 NO NO20090029A patent/NO20090029L/no not_active Application Discontinuation
- 2009-01-08 IL IL196391A patent/IL196391A0/en unknown
- 2009-01-08 CO CO09001490A patent/CO6150162A2/es unknown

Also Published As

Publication number	Publication date
MX2009000333A (es)	2009-03-13
EA200900136A1 (ru)	2009-06-30
IL196391A0 (en)	2009-09-22
ATE526331T1 (de)	2011-10-15
CA2690277A1 (fr)	2008-01-17
CN101511837A (zh)	2009-08-19
US20100105708A1 (en)	2010-04-29
AU2007271928A1 (en)	2008-01-17
US8697713B2 (en)	2014-04-15
JP2009542749A (ja)	2009-12-03
JP5331951B2 (ja)	2013-10-30
EP1889847A1 (fr)	2008-02-20
EP2041137A2 (fr)	2009-04-01
ZA200810785B (en)	2009-10-28
WO2008006547A2 (fr)	2008-01-17
CO6150162A2 (es)	2010-04-20
WO2008006547A3 (fr)	2008-03-06
BRPI0712882A2 (pt)	2012-10-09
EP2041137B1 (fr)	2011-09-28
KR20090039757A (ko)	2009-04-22

Publication	Publication Date	Title
NO20090029L (no)	2009-01-28	Pyrrolopyrimidiner for farmasoytiske formuleringer
WO2006066937A3 (fr)	2006-10-19	Nouvelle utilisation des pyrazolopyrimidines
EA200802118A1 (ru)	2009-04-28	Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
UY32072A (es)	2010-03-26	Tienopirimidinas para composiciones farmacéuticas
UY33246A (es)	2011-09-30	Tienopirimidinas que contienen cicloalquilo para composiciones farmacéuticas
TW200728305A (en)	2007-08-01	Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease
EA200900983A1 (ru)	2010-02-26	Соединения и композиции в качестве ингибиторов киназы
UY33241A (es)	2011-09-30	?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
WO2007058602A3 (fr)	2007-07-05	Nouveaux composes
PH12012501122A1 (en)	2012-10-29	Pteridinones as inhibitors of polo-like kinase
IL196543A (en)	2013-09-30	Pyridazinone derivatives, pharmaceutical preparations containing them for use in the treatment of disorders
WO2006044497A3 (fr)	2006-09-08	Composes de spiropiperidine utilises comme inhibiteurs de beta-secretase en vue du traitement de la maladie d'alzheimer
UY33245A (es)	2011-09-30	Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas
ATE456565T1 (de)	2010-02-15	Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren
MX2010014233A (es)	2011-03-25	Compuestos quimicos 251.
MY155836A (en)	2015-12-15	Thienopyridone derivatives as amp-activated protein kinase (ampk) activators
TNSN08444A1 (en)	2010-04-14	Bicyclic derivatives as cetp inhibitors
CR9347A (es)	2007-12-17	Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
TW200639155A (en)	2006-11-16	Thiazolidinones, their production and use as pharmaceutical agents
MX2007010400A (es)	2008-01-11	Nuevas sales de derivados de hexahidrofenantridina sustituida con 6-heterociclilo.
DE602004019778D1 (de)	2009-04-16	Verwendung von 2-amino-1,3-propandiolderivaten zur herstellung eines medikaments zur behandlung von bestimmten schmerzen
EA200801425A1 (ru)	2008-12-30	Диазепиноны
WO2007019078A3 (fr)	2007-07-12	Inhibiteurs de la beta-secretase tricyclique pour traiter la maladie d'alzheimer
UA86873C2 (en)	2009-05-25	SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES
MX2007013305A (es)	2007-12-13	Nuevas tiazolidinonas sin nitrogeno basico, su produccion y su uso como agentes farmaceuticos.

Legal Events

Date	Code	Title	Description
2011-02-28	FC2A	Withdrawal, rejection or dismissal of laid open patent application